HRP20171553T1 - Uporaba spojeva 4-(pirolidin-1-il)kinolina za uništavanje klinički latentnih mikroorganizama - Google Patents
Uporaba spojeva 4-(pirolidin-1-il)kinolina za uništavanje klinički latentnih mikroorganizama Download PDFInfo
- Publication number
- HRP20171553T1 HRP20171553T1 HRP20171553TT HRP20171553T HRP20171553T1 HR P20171553 T1 HRP20171553 T1 HR P20171553T1 HR P20171553T T HRP20171553T T HR P20171553TT HR P20171553 T HRP20171553 T HR P20171553T HR P20171553 T1 HRP20171553 T1 HR P20171553T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- phenylpyrrolidin
- quinolin
- formula
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D345/00—Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0709489A GB0709489D0 (en) | 2007-05-17 | 2007-05-17 | New use |
| GB0807591A GB0807591D0 (en) | 2008-04-25 | 2008-04-25 | New use |
| PCT/GB2008/001694 WO2008142384A1 (en) | 2007-05-17 | 2008-05-16 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
| EP08750626.7A EP2182950B8 (en) | 2007-05-17 | 2008-05-16 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171553T1 true HRP20171553T1 (hr) | 2017-12-15 |
Family
ID=39672613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171553TT HRP20171553T1 (hr) | 2007-05-17 | 2008-05-16 | Uporaba spojeva 4-(pirolidin-1-il)kinolina za uništavanje klinički latentnih mikroorganizama |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8759348B2 (enExample) |
| EP (1) | EP2182950B8 (enExample) |
| JP (1) | JP5474768B2 (enExample) |
| KR (1) | KR101599384B1 (enExample) |
| CN (1) | CN101795688B (enExample) |
| AU (1) | AU2008252636B2 (enExample) |
| BR (1) | BRPI0811745B1 (enExample) |
| CA (1) | CA2684692C (enExample) |
| DK (1) | DK2182950T3 (enExample) |
| ES (1) | ES2637999T3 (enExample) |
| HR (1) | HRP20171553T1 (enExample) |
| HU (1) | HUE034298T2 (enExample) |
| IL (1) | IL201392A (enExample) |
| MX (1) | MX2009012390A (enExample) |
| NZ (1) | NZ580625A (enExample) |
| PL (1) | PL2182950T3 (enExample) |
| PT (1) | PT2182950T (enExample) |
| RU (1) | RU2520766C2 (enExample) |
| SI (1) | SI2182950T1 (enExample) |
| WO (1) | WO2008142384A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010095522A (ja) * | 2008-09-19 | 2010-04-30 | Sumitomo Chemical Co Ltd | 植物病原菌による植物病害を防除又は予防するための農業用組成物 |
| CN102933212B (zh) * | 2010-03-30 | 2015-07-22 | 赫尔普百治疗有限公司 | 组合及应用 |
| MX2012013127A (es) * | 2010-05-13 | 2012-11-30 | Amgen Inc | Compuestos heteroariloxiheterociclilo como inhibidores pde10. |
| SI2600869T1 (sl) | 2010-08-05 | 2021-03-31 | Helperby Therapeutics Limited | Kombinacija spojine pirolokinolin in beta-laktamskega protimikrobnega sredstva, mupirocina in klorheksidina |
| GB201013207D0 (en) | 2010-08-05 | 2010-09-22 | Helperby Therapeutics Ltd | Novel combination |
| GB201015079D0 (en) | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| US20180214440A1 (en) | 2015-04-11 | 2018-08-02 | Helperby Therapeutics Limited | Oral composition |
| WO2017027768A1 (en) * | 2015-08-13 | 2017-02-16 | The Broad Institute, Inc. | Compositions and methods for treating tuberculosis |
| GB201518969D0 (en) | 2015-10-27 | 2015-12-09 | Helperby Therapeutics Ltd | Triple combination |
| US11253511B2 (en) | 2016-01-04 | 2022-02-22 | The Johns Hopkins University | Use of low dose emetine for inhibition of human cytomegalovirus (HCMV) |
| KR102665309B1 (ko) * | 2016-10-27 | 2024-05-10 | 주식회사 엘지생활건강 | 코디세핀을 포함하는 구강질환 예방 또는 치료용 조성물 |
| GB201703898D0 (en) | 2017-03-10 | 2017-04-26 | Helperby Therapeautics Ltd | Method |
| RU2664177C1 (ru) * | 2017-08-07 | 2018-08-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абсцедирующих фурункулов верхней и нижней зон лица |
| JP7269917B2 (ja) * | 2017-08-17 | 2023-05-09 | イケナ オンコロジー， インコーポレイテッド | Ａｈｒ阻害剤およびその使用 |
| JP6945083B2 (ja) | 2017-12-18 | 2021-10-13 | アンセラ セラピューティクス インコーポレイテッドＡｎｓｅｌｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 状態を予防及び治療するための組成物及び方法 |
| CN110897032B (zh) * | 2019-11-19 | 2025-10-14 | 华南理工大学 | 一种发酵饲料蛋白及其制备方法与应用 |
| RU2758056C2 (ru) * | 2019-11-21 | 2021-10-26 | федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный аграрный университет" | Препарат для лечения отитов бактериальной и грибковой этиологии у собак |
| CN111544599B (zh) * | 2020-07-10 | 2020-12-01 | 有术肌肤管理(深圳)有限公司 | 一种用于治疗痤疮的化合物及其用于制备药物或化妆品的用途 |
| KR102461715B1 (ko) * | 2020-10-12 | 2022-11-02 | 대한민국 | 항균 및 항진균 활성을 나타내는 신균주 페니실리움 비세티 및 이의 용도 |
| CN114831924A (zh) * | 2021-03-17 | 2022-08-02 | 武汉恒信源药业有限公司 | 一种乌洛托品及其化合物的阴道局部给药制剂及用途 |
| CN113528388A (zh) * | 2021-07-19 | 2021-10-22 | 海南大学 | 珊瑚共生链霉菌、发酵生产放线菌素d的方法及应用 |
| CA3237199A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW477787B (en) * | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
| EP1382603B1 (en) * | 2001-04-26 | 2008-07-23 | Eisai R&D Management Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
| KR100621287B1 (ko) * | 2001-05-21 | 2006-09-13 | 에프. 호프만-라 로슈 아게 | 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체 |
| US6787558B2 (en) * | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| EP1451156A4 (en) * | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-AMINOCHINOLINVERBINDUNGEN |
| WO2003066055A1 (en) * | 2002-02-04 | 2003-08-14 | F. Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| CN1678586A (zh) | 2002-06-27 | 2005-10-05 | 舍林股份公司 | 取代的喹啉ccr5受体拮抗剂 |
| EP1530495A2 (en) * | 2002-08-19 | 2005-05-18 | Avi Elbaz | Proprioceptive/kinesthetic apparatus and method |
| WO2004035569A2 (de) * | 2002-10-10 | 2004-04-29 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue verbindungen mit antibakterieller aktivität |
| CL2004000409A1 (es) * | 2003-03-03 | 2005-01-07 | Vertex Pharma | Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu |
| DE102004041163A1 (de) * | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| GB0522715D0 (en) * | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
-
2008
- 2008-05-16 AU AU2008252636A patent/AU2008252636B2/en not_active Ceased
- 2008-05-16 BR BRPI0811745-4A patent/BRPI0811745B1/pt not_active IP Right Cessation
- 2008-05-16 ES ES08750626.7T patent/ES2637999T3/es active Active
- 2008-05-16 HR HRP20171553TT patent/HRP20171553T1/hr unknown
- 2008-05-16 MX MX2009012390A patent/MX2009012390A/es active IP Right Grant
- 2008-05-16 RU RU2009146828/15A patent/RU2520766C2/ru not_active IP Right Cessation
- 2008-05-16 PT PT87506267T patent/PT2182950T/pt unknown
- 2008-05-16 NZ NZ580625A patent/NZ580625A/en not_active IP Right Cessation
- 2008-05-16 EP EP08750626.7A patent/EP2182950B8/en not_active Not-in-force
- 2008-05-16 WO PCT/GB2008/001694 patent/WO2008142384A1/en not_active Ceased
- 2008-05-16 KR KR1020097026394A patent/KR101599384B1/ko not_active Expired - Fee Related
- 2008-05-16 CA CA2684692A patent/CA2684692C/en not_active Expired - Fee Related
- 2008-05-16 CN CN200880016456.XA patent/CN101795688B/zh not_active Expired - Fee Related
- 2008-05-16 HU HUE08750626A patent/HUE034298T2/en unknown
- 2008-05-16 PL PL08750626T patent/PL2182950T3/pl unknown
- 2008-05-16 SI SI200831883T patent/SI2182950T1/en unknown
- 2008-05-16 US US12/600,470 patent/US8759348B2/en not_active Expired - Fee Related
- 2008-05-16 JP JP2010507981A patent/JP5474768B2/ja not_active Expired - Fee Related
- 2008-05-16 DK DK08750626.7T patent/DK2182950T3/da active
-
2009
- 2009-10-11 IL IL201392A patent/IL201392A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2684692C (en) | 2016-07-05 |
| DK2182950T3 (da) | 2017-11-06 |
| CN101795688A (zh) | 2010-08-04 |
| CN101795688B (zh) | 2015-05-20 |
| HUE034298T2 (en) | 2018-02-28 |
| MX2009012390A (es) | 2010-06-23 |
| RU2520766C2 (ru) | 2014-06-27 |
| RU2009146828A (ru) | 2011-06-27 |
| EP2182950A1 (en) | 2010-05-12 |
| US8759348B2 (en) | 2014-06-24 |
| KR20100021476A (ko) | 2010-02-24 |
| ES2637999T3 (es) | 2017-10-18 |
| JP2010527346A (ja) | 2010-08-12 |
| AU2008252636B2 (en) | 2013-10-31 |
| SI2182950T1 (en) | 2018-01-31 |
| NZ580625A (en) | 2011-12-22 |
| CA2684692A1 (en) | 2008-11-27 |
| EP2182950B1 (en) | 2017-07-19 |
| JP5474768B2 (ja) | 2014-04-16 |
| WO2008142384A1 (en) | 2008-11-27 |
| IL201392A0 (en) | 2010-05-31 |
| PT2182950T (pt) | 2017-09-11 |
| US20100305065A1 (en) | 2010-12-02 |
| BRPI0811745B1 (pt) | 2019-06-04 |
| EP2182950B8 (en) | 2017-08-23 |
| AU2008252636A1 (en) | 2008-11-27 |
| KR101599384B1 (ko) | 2016-03-03 |
| PL2182950T3 (pl) | 2018-01-31 |
| BRPI0811745A2 (pt) | 2014-11-11 |
| IL201392A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171553T1 (hr) | Uporaba spojeva 4-(pirolidin-1-il)kinolina za uništavanje klinički latentnih mikroorganizama | |
| JP2010527346A5 (enExample) | ||
| HRP20160043T1 (hr) | Uporaba spojeva pirolokinolina za suzbijanje kliniäśki latentnih mikroorganizama | |
| JP2009514936A5 (enExample) | ||
| WO2008117079B1 (en) | Antimicrobial compounds based upon 4-aminoquinoline | |
| JP4024309B2 (ja) | 新規な感染症治療薬 | |
| TWI444198B (zh) | 用於治療革蘭氏陽性菌感染的新穎抗菌劑 | |
| RU2012146093A (ru) | Новая комбинация и применение | |
| KR100652470B1 (ko) | 사이클로알킬 치환 아미노메틸피롤리딘 유도체 | |
| ES2238723T3 (es) | Derivados de aminociclopropano cis-sustituidos. | |
| KR100777149B1 (ko) | 데할로게노 화합물 | |
| CN108602822A (zh) | 含有7-氧代-6-(硫氧基)-1,6-二氮杂双环[3.2.1]辛烷-2-甲酰胺的化合物及其在治疗细菌感染中的用途 | |
| Shi et al. | Design, synthesis, and antibacterial activity of 2, 5-dihydropyrrole formyl hydroxyamino derivatives as novel peptide deformylase inhibitors | |
| WO1998052939A1 (en) | Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives | |
| EP3215496B1 (en) | Pantothenamide analogues | |
| RU2298006C2 (ru) | Дегалогенированные соединения, антибактериальное средство и терапевтическое средство на их основе, способ получения антибактериального или лекарственного средства, применение дегалогенированных соединений для получения антибактериального или лекарственного средства | |
| JPH1081682A (ja) | シス置換アミノシクロプロパン誘導体 | |
| HK1140146A (en) | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | |
| HK1140146B (en) | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | |
| MXPA01005206A (en) | Cycloalkyl-substituted aminomethylpyrrolidine derivatives |